Several diarylamide compounds have been highlighted as potential anticancer agents. Among them, imatinib, dasatinib, and nilotinib have been marketed for treatment of chronic myeloid leukemia (CML). CML is a cancer type that originates in specific cells in bone marrow and is considered as life-threating disease. Imatinib is the first generation of tyrosine kinase inhibitor (TKI) to be approved for treatment of CML. Second generation drugs, dasatinib and nilotinib, were introduced for patients that are resistant or intolerant to imatinib therapy. Second generation drugs induce faster responses with fewer side effects when compared to imatinib. In this literature review, we reviewed recent advances of diarylamide anticancer agents, including first and second generation drugs treating CML and their other uses, in addition to other compounds that are still in preclinical phases. This review focuses on the reports published in the literature from 2010 to 2019.

中文翻译：

---

二芳基酰胺类药物在抗癌药物中的作用：临床前和临床研究综述。

几种二芳基酰胺化合物已被强调为潜在的抗癌剂。其中，伊马替尼，达沙替尼和尼洛替尼已投放市场用于治疗慢性粒细胞白血病（CML）。CML是一种癌症类型，起源于骨髓中的特定细胞，被认为是威胁生命的疾病。伊马替尼是第一批被批准用于治疗CML的酪氨酸激酶抑制剂（TKI）。针对伊马替尼治疗耐药或不耐受的患者，引入了第二代药物达沙替尼和尼洛替尼。与伊马替尼相比，第二代药物诱导更快的反应且副作用更少。在这篇文献综述中，我们回顾了二芳基酰胺抗癌药的最新进展，包括治疗CML的第一代和第二代药物及其其他用途，除了仍处于临床前阶段的其他化合物。这篇综述着重于2010年至2019年文献中发表的报告。